Supported by National Eye Institutes Grants EY11008, P30 EY022589, EY026590, EY022039, EY021818, and T32 EY026590; and a Genentech, Inc. Unrestricted grant from Research to Prevent Blindness (New York, NY, USA).
Disclosure: M. Christopher, None; A. Belghith, None; R.N. Weinreb, Aerie Pharmaceuticals (C), Alcon (C), Allergan (C), Bausch & Lomb (C), Carl Zeiss Meditec (F), Centervue (F), Genentech (F), Heidelberg Engineering (F), Konan (F), Novartis (C), Optos (F), Optovue (F), Topcon (F), Valeant (C); C. Bowd, None; M.H. Goldbaum, None; L.J. Saunders, None; F.A. Medeiros, Alcon (F), Allergan (F, C), Bausch & Lomb (F), Carl Zeiss Meditec (F, C), Heidelberg Engineering (F), Merck (F), National Eye Institute (F), Novartis (C), Reichert (F), Sensimed (F), Topcon (F); L.M. Zangwill, Carl Zeiss Meditec (F), Heidelberg Engineering (F), Optovue (F), Topcon Medical System, Inc. (F)